tavapadon   Click here for help

GtoPdb Ligand ID: 13372

Synonyms: CVL-751 | Juvmo® | PF-06649751
Approved drug PDB Ligand
tavapadon is an approved drug
Compound class: Synthetic organic
Comment: Tavapadon (CVL-751) is an orally bioavailable, brain-penetrant, non-catechol dopamine D1/D5 receptor partial agonist [3-4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 71
Molecular weight 391.34
XLogP 1.61
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=C(C=CC(=C1)OC2=NC=CC=C2C(F)(F)F)C3=C(C)C(=O)NC(=O)N3C
Isomeric SMILES CC1=C(C=CC(=C1)OC2=C(C=CC=N2)C(F)(F)F)C3=C(C(=O)NC(=O)N3C)C
InChI InChI=1S/C19H16F3N3O3/c1-10-9-12(28-17-14(19(20,21)22)5-4-8-23-17)6-7-13(10)15-11(2)16(26)24-18(27)25(15)3/h4-9H,1-3H3,(H,24,26,27)
InChI Key AKQXQLUNFKDZBN-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Tavapadon (CVL-751) was progressed to phase 3 clinical evaluation for the treatment of the motor symptoms of Parkinson's disease. First approval was granted for this indication by the US FDA in September 2026.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02847650 Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease Phase 2 Interventional Pfizer 2
NCT02224664 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease Phase 1 Interventional Pfizer 3
NCT02373072 A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease Phase 1 Interventional Pfizer 3
NCT04542499 Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations Phase 3 Interventional Cerevel Therapeutics, LLC
NCT04201093 Fixed-Dose Trial in Early Parkinson's Disease (PD) Phase 3 Interventional Cerevel Therapeutics, LLC
NCT04223193 Flexible-Dose Trial in Early Parkinson's Disease (PD) Phase 3 Interventional Cerevel Therapeutics, LLC
NCT04760769 Open-label Trial in Parkinson's Disease (PD) Phase 3 Interventional Cerevel Therapeutics, LLC